Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Nomination committee propose new board members in Mentice AB prior to convening an Extraordinary Shareholders’ Meeting on August 28, 2019

Wednesday, July 31, 2019

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee proposes that the board be extended with three members to a total of seven members. The nomination committee intends to suggest the election of Denis Gestin, Gösta Johannesson and David Ballard.

The nomination committee proposes that the extraordinary shareholders’ meeting resolves to approve and appoint three new board members to the board of directors. The board of directors propose that the following persons shall be appointed to new ordinary board members in the board of directors:

Denis Gestin, born 1964, B.Sc in Business Administration and Economics, chairman of the board in Holistick Medical, France, and Endo Tools Therapeutics and board member of Acarix. Denis Gestin is independent in relation to the company, its management and major shareholders.

Gösta Johannesson, born 1959, B.Sc in Business Administration and Economics, senior adviser Bure Equity, chairman of the board XVIVO Perfusion, Idevall & Partners fonder, deputy chairman of Interflora and Axiell Group, board member of Yubico and others. Gösta Johannesson is independent in relation to the company, its management but not in relation to one major shareholder.

David Ballard, born 1956, B.Sc. in Economics, Medical Doctor degree, M. Sc. In Public Health and PhD in Epidemiology, Executive Vice President and Chief Clinical Officer in Mentice and member of the advisory committee for Mentice Inc and Robbins Institute for Health Policy and Leadership, Baylor University. David Ballard is independent in relation to the major shareholders but not in relation to the company and its management. If elected as a member of the board, David Ballard will be operating purely as a consultant for Mentice and will consequently immediately leave his line management positions and his seat in the executive management team.

Furthermore, the board of directors propose that the extraordinary shareholders’ meeting shall resolve to approve that a fixed yearly fee of in total SEK 530,000 shall be paid to the new members of the board of directors.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Nomination committee propose new board members in Mentice AB prior to convening an Extraordinary Shareholders’ Meeting on August 28, 2019

Wednesday, July 31, 2019

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee proposes that the board be extended with three members to a total of seven members. The nomination committee intends to suggest the election of Denis Gestin, Gösta Johannesson and David Ballard.

The nomination committee proposes that the extraordinary shareholders’ meeting resolves to approve and appoint three new board members to the board of directors. The board of directors propose that the following persons shall be appointed to new ordinary board members in the board of directors:

Denis Gestin, born 1964, B.Sc in Business Administration and Economics, chairman of the board in Holistick Medical, France, and Endo Tools Therapeutics and board member of Acarix. Denis Gestin is independent in relation to the company, its management and major shareholders.

Gösta Johannesson, born 1959, B.Sc in Business Administration and Economics, senior adviser Bure Equity, chairman of the board XVIVO Perfusion, Idevall & Partners fonder, deputy chairman of Interflora and Axiell Group, board member of Yubico and others. Gösta Johannesson is independent in relation to the company, its management but not in relation to one major shareholder.

David Ballard, born 1956, B.Sc. in Economics, Medical Doctor degree, M. Sc. In Public Health and PhD in Epidemiology, Executive Vice President and Chief Clinical Officer in Mentice and member of the advisory committee for Mentice Inc and Robbins Institute for Health Policy and Leadership, Baylor University. David Ballard is independent in relation to the major shareholders but not in relation to the company and its management. If elected as a member of the board, David Ballard will be operating purely as a consultant for Mentice and will consequently immediately leave his line management positions and his seat in the executive management team.

Furthermore, the board of directors propose that the extraordinary shareholders’ meeting shall resolve to approve that a fixed yearly fee of in total SEK 530,000 shall be paid to the new members of the board of directors.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: 
goran.malmberg@mentice.com

US Mobile. +1 (312) 860 5610

Sweden Mobile +46 (0) 703 09 22 22

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399